Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma
Hepatocellular Carcinoma
DRUG: Sintilimab|DRUG: Bevacizumab|COMBINATION_PRODUCT: Liver Protective Support Therapy
Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, Up to 3 years|Overall survival (OS), Defined as the time from the date of treatment start to the date of death, Up to 3 years
Overall response rate (ORR), Defined as proportion of patients who have a best response of CR or PR, Up to 1 years|Disease control rate (DCR), Defined as proportion of patients who have a best response of CR, PR or SD, Up to 1 years|Quality of Life (QoL), The improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0), Up to 3 years
To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma